Effect of 13-Week Treatment With Vildagliptin as Add-On Therapy to Improve Glucose Variability in Type II Diabetes
Status:
Terminated
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess if the addition of vildagliptin as add-on therapy
improves glucose variability in type 2 diabetes mellitus (T2DM) patients inadequately
controlled with insulin, with special emphasis in hypoglycemic episodes measured by
continuous glucose monitoring.